Article Text

Download PDFPDF
Rivaroxaban plus aspirin for secondary prevention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aspirin is well established in the secondary prevention of cardiovascular disease. In a meta-analysis of 16 secondary prevention trials (17,000 participants), aspirin has been shown to reduce serious vascular events (6.7% vs 8.2% per year, p<0.0001) with reductions in total stroke (2.08% vs 2.54% per year, p=0.002) and in coronary events (4.3% vs. 5.3% per year, p<0.0001).1 A trial has assessed whether rivaroxaban alone or in combination with aspirin is more …

View Full Text